Corcept Therapeutics vs Ionis Pharmaceuticals
CORT and IONS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CORT and IONS compare
Corcept Therapeutics is the larger company, worth 1.2 times as much as Ionis Pharmaceuticals ($8.8B against $7.2B).
Corcept Therapeutics grew revenue faster over the last twelve months (16.0% versus −7.4% for Ionis Pharmaceuticals).
Corcept Therapeutics keeps more of each dollar of sales as profit, with a net margin of 6.6% compared with −64.7% at Ionis Pharmaceuticals.
Corcept Therapeutics scores higher on the StockData Score (11 against 3 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CORT | IONS |
|---|---|---|
| Size and price | ||
| Market cap | $8.8B | $7.2B |
| Share price | $81.12 | $43.52 |
| Change, 1 year | 12.6% | −39.5% |
| Change, 5 years | 292% | 29.2% |
| Beta (5Y) | 0.55 | 0.71 |
| Employees | 730 | 1,402 |
| StockData Score | ||
| Total score | 11 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 2 (better) | 0 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 193× | – |
| P/S | 10.6× | 8.3× (better) |
| P/B | 12.4× (better) | 16.4× |
| EV/EBITDA | 1047× | – |
| P/FCF | 82.0× | – |
| FCF yield | 1.2% (better) | −7.8% |
| Fair value | $15.98 | $28.12 |
| Margin of safety | −408% | −54.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 16.0% (better) | −7.4% |
| Revenue growth, 5Y average | 16.6% (better) | 5.3% |
| Net income growth (TTM) | −58.7% | – |
| EPS growth (TTM) | −62.5% | – |
| EPS growth, 5Y average | −0.72% | – |
| Profitability | ||
| Gross margin | 98.3% (better) | 98.2% |
| Operating margin | 0.77% (better) | −68.0% |
| Net margin | 6.6% (better) | −64.7% |
| FCF margin | 12.9% (better) | −64.2% |
| Return on equity | 8.2% (better) | −105% |
| Return on invested capital | 1.9% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −31.6× |
| Current ratio | 2.86 | 7.89 (better) |
| Altman Z-score | 31.14 (better) | 0.88 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | 0.48% | – |
| Shareholder yield | 0.48% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 76.2% | 108% |
| Held by insiders | 14.4% | 0.80% |
| Insider net buying, 12 months | −$92.1M (better) | −$123M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 9.2% | 13.7% |
Go deeper
- CORT stock overview
- CORT income statement
- CORT valuation and score
- IONS stock overview
- IONS income statement
- IONS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.